Invivyd, Inc.
IVVDNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $53.4M | $25.4M | $0 | — | — | — |
| Operating income | −$55.6M | −$176.9M | −$212.8M | −$248.0M | −$226.9M | −$65.3M |
| Net income | −$52.5M | −$169.9M | −$198.6M | −$241.3M | −$226.8M | −$65.3M |
| Total assets | $276.9M | $129.5M | $229.2M | $383.2M | $620.1M | $117.4M |
| Total liabilities | $35.3M | $62.0M | $51.7M | $27.2M | $62.1M | $13.1M |
| Equity | $241.5M | $67.5M | $177.5M | $356.0M | $558.0M | −$65.2M |
| EPS (diluted) | $-0.30 | $-1.43 | $-1.81 | $-2.23 | $-5.32 | — |
| Shares out. | 120.0M | 119.2M | 109.2M | 109.7M | 110.8M | 5.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −104.0%
- Net margin
- −98.2%
- Return on equity
- −21.7%
- Return on assets
- −19.0%
- Return on capital (ROCE)
- −22.9%
- Liabilities / assets
- 12.8%
- Debt / equity
- 0.15×
- Book value / share
- $2.01
- Revenue growth (YoY)
- 110.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -0.36distress
- Accruals / assets
- 2.0%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2025-05A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants
- Phase 3Recruitingreadout ~2026-08Study of VYD2311 for the Prevention of COVID-19
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ra Capital Management, L.P.Passive (13G)May 15, 2026
- Point72 Asset Management, L.P.Passive (13G)May 15, 2026
- Biotechnology Value Fund L PPassive (13G)Feb 17, 2026
- Maverick Capital LtdPassive (13G)Feb 13, 2026
- Soleus Private Equity Fund Iii, L.P.Passive (13G)Feb 12, 2026
- Adimab, LlcActivist (13D)Dec 29, 2025
- Perceptive Advisors LlcPassive (13G)Nov 25, 2025
- Janus Henderson Group PlcPassive (13G)Nov 14, 2025
- Deep Track Capital, LpPassive (13G)Nov 14, 2025
- Mithril Ii LpActivist (13D)Nov 12, 2025
- Polaris Venture Partners V, L.P.Activist (13D)Nov 7, 2025
- M28 Capital Management LpActivist (13D)Aug 26, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Allen Robert D. IiiOfficer — Chief Scientific Officer | Feb 15, 2026 | Option exercise | 99,000 | — |
| Green JulieOfficer — Chief Human Resources Officer | Feb 15, 2026 | Option exercise | 99,000 | — |
| Duke William E.Officer — Chief Financial Officer | Feb 15, 2026 | Option exercise | 99,000 | — |
| Lee Timothy EdwardOfficer — Chief Commercial Officer | Feb 15, 2026 | Option exercise | 99,000 | — |
| Andersen JillOfficer — Chief Legal Officer, Secretary | Feb 15, 2026 | Option exercise | 165,000 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 31.1M | 9.5 | +6.2% |
| Apr 30, 2026 | 29.3M | 21.8 | +0.0% |
| Apr 15, 2026 | 29.3M | 5.6 | +10.5% |
| Mar 31, 2026 | 26.5M | 8.4 | +7.9% |
| Mar 13, 2026 | 24.5M | 10.3 | +8.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 19, 2026
- Results of operations · Other material eventMay 14, 2026
- Other material eventApr 9, 2026
- Results of operations · Other material eventMar 5, 2026
- Results of operations · Other material eventJan 8, 2026
- Other material eventDec 23, 2025
- Other material eventNov 24, 2025
- Entered a material agreement · Other material eventNov 19, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.